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Introduction.
Vascular proliferative disorders, such as atherosclerosis, restenosis after balloon angioplasty, and vein-graft disease are the most common causes of severe cardiovascular disease. Eventually, arterial wall thickening, plaque rupture, and occlusion lead to the clinical manifestations of cardiovascular disease (eg, myocardial infarction and stroke), the current leading cause of morbimortality in developed countries [1] [2] . An important common etiological factor in these inflammatory disorders is the development of neointimal lesions caused by the accumulation of circulating leukocytes, vascular smooth muscle cells (VSMCs), and noncellular material (eg., circulating lipoproteins, extracellular matrix components). Under normal conditions, VSMCs residing within the arterial tunica media display a so-called 'contractile' phenotype characterized by low proliferative and migratory activity and expression of differentiation markers (eg., contractile proteins). However, unlike terminally differentiated striated muscle cells, VSMCs can revert to a 'synthetic' phenotype featuring suppression of differentiation marker gene expression, abundant synthesis of extracellular matrix components, and high proliferative and migratory activity 3 . These pathological processes are induced by a variety of pathological stimuli, such as atherogenic stimuli, mechanical stress of the vessel wall, and vessel denudation 2 . Thus, VSMCs phenotypic switching, hyperproliferation and migration into the neointimal layer of the arterial wall are essential components of neointimal lesion development.
Multiple signalling pathways and molecular networks appear to control VSMCs growth in response to pathological insults [4] [5] . Recently, it has been reported that the mitofusin-2 (Mfn2) gene, also named hyperplasia suppressor gene (HSG), encodes a protein whose dysregulation is involved in vascular proliferative disorders 6 . This conclusion is based on a variety of observations, namely: a) Mfn2 expression is down-regulated in hyperproliferative VSMCs from spontaneously hypertensive rat arteries, balloon-injured Wistar Kyoto rat arteries and apolipoprotein E-knock-out (Apo E-KO) mouse atherosclerotic arteries; and b) adenoviral-mediated over-expression of Mfn2 suppresses serum-dependent proliferation of cultured VSMCs, and attenuates balloon injury-induced neointimal VSMC growth and vascular occlusive lesion development in rat carotid arteries. Nevertheless, the functional role of Mfn2 is complex and not limited to the regulation of cell proliferation.
Mfn2 is a mitochondrial outer membrane protein that primarily participates in mitochondrial fusion 7 , activates mitochondrial metabolism in mammalian cells [8] [9] , and protects against apoptosis 10 . Recently, it has been reported that Mfn2 is enriched at the endoplasmic reticulum-mitochondria interface, and that Mfn2 in the endoplasmic reticulum is required for efficient mitochondrial Ca 2+ uptake and normal ER morphology. This gene is essential in rodents, as mice deficient in Mfn2 die in midgestation, probably because of impaired placental function caused by a marked reduction in the number of polyploid giant cells of the placental trophoblast 11 . Studies in conditional knockout mice indicate that Mfn2 is required for proper development and maintenance of the cerebellum, and that Purkinje cells require Mfn2 for their extensive dendritic outgrowth and survival. In humans, Mfn2 mutations cause CharcotMarie-Tooth type 2A 12 , an autosomal dominant neuropathy. In addition, skeletal muscle
Mfn2 is deficient in human obesity and in type 2 diabetes, which suggests that this gene may be involved in the pathophysiology of these metabolic diseases 8 . On the basis of these observations, the present study was designed to ascertain the mechanisms that regulate Mfn2 transcription by investigating the promoter region of human Mfn2.
Methods.
Cloning of human Mfn2 promoter. A human Mfn2 promoter fragment containing positions -1982 to +45 from the transcription start site was prepared by PCR amplification using human genomic DNA templates, and the following primers: 5'-cccgggaggcagaggttgtagtgagttgag-3' and 5'-gaggcgggaggagggaagtggata-3'. The amplified DNA fragment was digested with SacI and SmaI and cloned into the SacI/SmaI sites of pGL3-promoterless vector (Promega).
Databases and computer analysis. Potential transcription factor-binding sites were mapped to the Mfn2 promoter using AliBaba (http://www.alibaba2.com) and TESS (http://www.cbil.upenn.edu/tess/) software. CpG islands were located using the CpGPlot program (http://www.ebi.ac.uk/emboss/cpgplot/).
Cell culture. Primary rat aorta VSMCs, C3H10T1/2 cells, and the L6E9 rat skeletal muscle cell line were used. Primary rat aorta VSMCs were prepared as previously described 13 . Aorta were collected from adult male Wistar rats euthanized in a CO 2 chamber followed by cervical dislocation. Arteries were dissected free from surrounding tissue and adventitia and cut into small pieces. Aortic tissue was digested with collagenase (2 mg/ml, Worthington Figure 1A ). Estrogen-related receptor-α (ERRα)-binding element, which is required for PGC-1 and PGC-1 stimulation of Mfn2 promoter is also shown [14] [15] .
The region near exon 1 is TATA-less, but it contains a G/C-rich region bearing several potential Sp1-binding motifs ( Figure 1A ). The mouse ( Figure 1B ) and rat (Supplementary CpG islands are defined as sequences larger than 200 bp with a proportion of C+G greater than 50% and with a CpG observed/CpG expected ratio of 0.6 or higher 16 . Using the CpGPlot program, analysis of the human Mfn2 promoter region from -600 to +600 (relative to the transcription initiation site) revealed a CpG island that lies between -266 and +362
(Supplementary Figure 2) . A CpG island was also detected in the mouse Mfn2 promoter between -316 and +225, and rat Mfn2 promoter between -278 and +113 (data not shown).
Based on the CpG ratio, GC content and length of the CpG-rich region, the Mfn2 promoter is defined as a High-CpG promoter (HCP) that represents a strong CpG island 17 .
In vertebrates, CpG islands are predominantly non-methylated 18 . Non-methylated CpG islands are organized in a characteristic chromatin structure that predisposes them toward promoter activity. As Mfn2 expression has been shown to be ubiquitous, we hypothesized that Mfn2 promoter CpG island should be in a non-methylated state in vivo. To Mfn2 shows multiple transcription start sites.
TATA-less promoters that contain CpG islands usually initiate transcription from multiple weak start sites, which are often distributed over a region of about 100 bp 19 . 5'-RACE was performed to determine whether transcription start sites (TSSs) other than those found in the GeneBank and localized at +1 and +142. We used a commercial 5'-RACE-ready kit with an adapter linked only to mRNA with CAP (from human skeletal muscle) to avoid the amplification of partially degraded mRNA, and nested primers located in exon 2. Several bands were detected after 5'-RACE (Supplementary Figure 3A) , which were cloned in the T- produced a progressive loss in promoter activity (~70-fold greater activity than the promoterless construct) ( Figure 3A ). Construct +123/+348-Luc did not show significant differences in luciferase activity compared to the promoterless vector ( Figure 3A ). Although the +123/+348
Mfn2 fragment maintained the TSS6, its loss of promoter activity may be attributable to the lack of 5' sequences required for the positioning of basal transcription machinery. Given that TSS2 and TSS5 are the two most represented TSSs found by RACE analysis, we next examined their relevance for Mfn2 promoter activity. To this end, the related Inr elements in TSS2 and TSS5 in -229/+348-luc were subjected to mutagenesis by substituting the A +1 and the base at position +3 by G and C, respectively, which greatly reduces Inr activity both in vitro and in vivo 21 . As commonly found in other CpG island-containing promoters (18) , single TSS2 or TSS5 mutations did not modify the activity of the -229/+348 promoter in transient transfection assays, but double mutants showed a 50% reduction in this activity ( Figure 3B ).
Identification of the core promoter of human Mfn2.
Next, we aimed to identify the functionally relevant cis-regulatory elements in the Thus, endogenous Sp1 binds to Mfn2 promoter in primary VSMCs and L6E9 cells.
Considering that Sp1 binds to Mfn2 promoter and increases Mfn2 promoter activity in cell cultures, we wanted to assess if this effect/phenotype was also present in a more physiological in vivo model. Consistent with previous studies showing reduced Mfn2 expression in arteries from Apolipoprotein E-null mice (ApoE-KO) subjected to a high-fat diet (6), we found a marked reduction in Sp1 mRNA levels in aorta from Apo E-KO mice fed an atherogenic diet for 1 week (50% decrease versus control diet) ( Figure 5C , left panel).
Under these conditions, Mfn2 mRNA levels also underwent a significant reduction (60% decrease) ( Figure 5C , right panel). The effects of an atherogenic diet were transient and no effects on Sp1 or Mfn2 gene expression were detected in aorta after more prolonged treatment (2 months) (data not shown). These data suggest that downregulation of Sp1 at the onset of atherosclerosis contributes to reduced Mfn2 transcription in aortic tissue. A similar coregulation of Sp1 and Mfn2 was detected upon culturing VSMCs in normal (10% FBS) or low serum (0.2% during 48h) conditions. Total RNA was obtained and real-time PCR assays were performed. Sp1 gene expression was lower in VSMCs cultured in 0.2% FBS than in the normal serum condition ( Figure 5D , left panel). Accordingly, Mfn2 mRNA levels were also downregulated in this situation ( Figure 5D , right panel).
Searching for the in vivo effects of Sp1 depletion on Mfn2 protein expression, a shRNA approach was used. In order to knock down Sp1 expression, we infected VSMCs and L6E9 cultures with lentivirus encoding specific Sp1 shRNA (shSp1) or scramble control sequences (C). Western blot analysis revealed an almost total depletion of Sp1 protein in shSp1 transduced VSMCs and an 85% downregulation in shSp1 transduced L6E9 cells ( Figure 6A and B).
In order to evaluate the impact of Sp1 loss-of-function on Mfn2 promoter activity control and Sp1 depleted cells were transfected with the -532/+45-pGL3 or -229/-54-pGL3
and promoter activity was tested. As expected, the luciferase assay showed a significant decrease in promoter activity in Sp1 knock-down cells compared to controls ( Figure 6C ), The construct containing the -1984/+45 promoter region showed the same result (data not shown).
Thus, these data confirms the essential role of Sp1 in Mfn2 promoter activation.
Sp1 consensus binding sites are target for specific inhibitors. Thus, next we examined the role of Sp1 in the control of Mfn2 gene expression, by using WP631, a specific inhibitor of Sp1 [22] [23] . For this purpose, L6E9 cells transfected with -532/+45-pGL3 or -229/-54-pGL3
constructs were incubated in the presence of 300 nM WP631 during 24h. As shown in Figure   6D , WP631 caused a 90% inhibition in luciferase activity for both constructs. In order to further assay WP631 action, we incubated primary rat VSMCs with the compound and 
Discussion.
In the present study, we have both identified and characterized the promoter regions of human, mouse and rat Mfn2 genes. These promoters contain a region of approximately 500 bp which satisfies the criteria for the presence of a strong CpG island (15, 16) . Under in vivo conditions no evidence for methylation has been found, which is in agreement with data indicating that strong CpG islands-containing promoter are not methylated 17, 24 . We have also
shown that the human Mfn2 promoter is TATA-less and that the -229/+123 region, which The Mfn2 promoter represents a model to understand the elements responsible for the core promoter function of promoters located in CpG islands. This aspect is particularly relevant since the specific mechanisms that control the activity of promoters located in CpG islands are not well understood 19 in spite of the fact that almost 60% of the promoter regions of human genes are located within these islands 26 . Using 5'-RACE, we found that transcription of Mfn2 in human skeletal muscle can be initiated in at least 6 TSS, which show homology with Inr elements, a common feature of promoters in CpG islands 19 . The two main transcriptional start points identified by sequencing of 5'-RACE products, TSS2 and TSS5, were mutated to examine their functional importance. Individually, mutation did not change the strength of the promoter although the double mutant reduced promoter activity by 50%.
These results indicate that the human Mfn2 gene constitutes a redundant system capable of maintaining high promoter activity even after mutation of the most frequently used individual In conclusion, Sp1 binds to the Mfn2 promoter in different cells types, which includes VSMCs and skeletal muscle cells, and transactivates the basal machinery of Mfn2. Sp1 has been reported to inhibit VSMCs proliferation by induction of p27 and by repression of p21 expression and cyclin D1-Cdk4-p21 complex formation [29] [30] . In this study we provide evidence for a stimulatory role of Sp1 on Mfn2 expression in VSMCs. Based on the antiproliferative action of Mfn2 in VSMCs, our data reveal a new mechanism by which Sp1 may prevent the development of vascular proliferative disease. B) The region -229/-54 was deleted in the construction -532/+45-Luc by restriction digestion.
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Supplementary Data Supplementary Methods
Cell culture. Cells were cultured in a humidified atmosphere with 5% CO 2 at 37 ºC.
C3H10T1/2 cells were grown in DMEM supplemented with 10% FBS and 100 units/ml penicillin and 100 µg/ml streptomycin. Primary rat aorta VSMCs were prepared as previously described 1 and were grown in DMEM-F12 (1:1) supplemented with 10% FBS, 2 mM glutamine, 0.25 µg/ml fungizone, 100 units/ml penicillin and 100 µg/ml streptomycin and 25 mM Hepes. Preconfluent VSMCs were induced to differentiate by incubating them in medium containing 0.5% FBS during 48h. The L6E9 rat skeletal muscle cell line was cultured in DMEM containing 10% FBS, 100 units/ml penicillin G and 100 µg/ml streptomycin and 25
mM Hepes (pH 7.4) (Growth Medium). Pre-confluent myoblasts (80-90%) were induced to differentiate by lowering FBS to a final concentration of 2% (vol/vol) (Differentiation Medium). Cells were completely differentiated after 4 days in this medium. INS-1 rat insulinoma cell line was cultured in RPMI 1640 supplemented with 10% FBS, 10 mM Hepes (pH 7.4), 1 mM sodium piruvate, 50 µM beta-mercaptoethanol, 2 mM glutamine, 100 units/ml penicillin G and 100 µg/ml streptomycin. H4IIE rat hepatoma cell line was cultured in DMEM supplemented with 10% FBS, 100 units/ml penicillin G and 100 µg/ml streptomycin. FAO rat hepatoma cell line was cultured in F-12 Coon´s Modification (Sigma) supplemented with 10% FBS, 2 mM glutamine, 100 units/ml penicillin G and 100 µg/ml streptomycin.
In vivo studies. Four-month-old Apo E-KO mice (C57BL/6J, Charles River) were fed either control chow or an atherogenic (ATG) diet for 1 week (10.8% total fat, 0.75% cholesterol, S8492-E010, Ssniff, Germany). After sacrifice, the aorta was collected (pooled from 1 male and one female), immediately snap-frozen and stored at -80ºC. For some other purposes, 
